MetaVia to Present at the Emerging Growth Conference in December
NRBO 12.02.2024
CAMBRIDGE, Mass.,Dec. 2, 2024/PRNewswire/ --MetaVia Inc.(Nasdaq:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced thatHyung Heon Kim, President and Chief Executive Officer andMarshall H. Woodworth, Chief Financial Officer, will present a company update at the Emerging Growth Conference onWednesday, December 4, 2024at4:10 pm ET.
After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance toquestions@emerginggrowth.com, or ask your questions during the event.
Please register using thislinkto attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contactMichael Milleratmmiller@rxir.com.
About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
For more information, please visitwww.metaviatx.com.
Contacts:
MetaViaMarshall H. WoodworthChief Financial Officer+1-857-299-1033marshall.woodworth@metaviatx.com
Rx Communications GroupMichael Miller+1-917-633-6086mmiller@rxir.com
SOURCE MetaVia Inc.